Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2167124

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2012

Description:

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2012', provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutic pipeline. This report provides information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma). 'Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Basal Cell Carcinoma (Basal Cell Epithelioma).
- A review of the Basal Cell Carcinoma (Basal Cell Epithelioma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline depth and focus of Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutic Products under Development, Key Players in Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics, Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline Overview, Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline, Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline Assessment

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Basal Cell Carcinoma (Basal Cell Epithelioma) Overview
Therapeutics Development
An Overview of Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma)
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics under Development by Companies
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Products under Development by Companies
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics Development
F. Hoffmann-La Roche Ltd.
Biofrontera AG
Millennium Pharmaceuticals, Inc.
Novartis AG
LEO Pharma A/S
Moberg Derma AB
Basal Cell Carcinoma (Basal Cell Epithelioma) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Erivedge - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ameluz - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Picato - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HPPH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Silicon Phthalocyanine 4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LDE225 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LDE225 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imiquimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Celecoxib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Itraconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LEQ506 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dz13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAK-441 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Limtop - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Drug Profile Updates
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics - Dormant Products
Basal Cell Carcinoma (Basal Cell Epithelioma) – Product Development Milestones
Featured News & Press Releases
Jun 07, 2012: Curis Announces Publication Of Erivedge Data In New England Journal Of Medicine
May 17, 2012: Curis Announces Presentation Of Erivedge Clinical Data At ASCO Annual Meeting
May 07, 2012: Curis Announces Collaborator Roche's Submission Of Erivedge For Registration With Australian Regulatory Authority
Mar 09, 2012: Moberg Derma Receives Approval To Initiate Clinical Trial For Limtop
Jan 30, 2012: Curis Announces FDA Approval Of Erivedge Capsule As First Treatment For Advanced Basal Cell Carcinoma
Dec 22, 2011: Curis Announces Roche's Submission Of Marketing Authorization Application For Vismodegib In Advanced Basal Cell Carcinoma
Nov 15, 2011: Moberg Derma Receives SEK4m From Vinnova For Development Of Limtop
Nov 09, 2011: Curis Announces FDA Acceptance And Priority Review Of NDA For Vismodegib As Treatment For Advanced Basal Cell Carcinoma
Sep 12, 2011: Genentech Submits New Drug Application To FDA For Vismodegib For Basal Cell Carcinoma
Jun 20, 2011: Roche Reports Positive Results From Phase II Study Of Carcinoma Drug
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2012
Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Biofrontera AG, H1 2012
Millennium Pharmaceuticals, Inc., H1 2012
Novartis AG, H1 2012
LEO Pharma A/S, H1 2012
Moberg Derma AB, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Drug Profile Updates
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2012
Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2

Printed Tuesday, May 21, 2013
11:37:51 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2012

Web Address

http://www.researchandmarkets.com/reports/2167124

Office Code

OC8DIQSQNMUVPS

Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		EURO€ 384.00
Electronic (PDF) - Site License		EURO€ 769.00
Electronic (PDF) - Enterprisewide		EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

                Title:
            
                    Mr
                    
                    Mrs
                    
                    Dr
                    
                    Miss
                    
                    Ms
                    
                    Prof
                    
                First Name:
            
                Last Name:
                
                Email Address:
            
                Job Title:
            
                Organisation:
            
                Address:
            
                City:
            
                Postal / Zip Code:	
            
                Country:	
            
                Phone Number:	
            
                Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2

Printed Tuesday, May 21, 2013
11:37:51 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:

Cardholder's Signature:

Expiry Date:

Card Number:

CVV Security Code:

Issue date:

(Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:

83313083

Sort Code:

98-53-30

Swift Code:

ULSBIE2D

IBAN Number:

IE78ULSB98533083313083

Bank Address:

Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Printer Friendly

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2012

Fax order form

Order information

Product name

Web Address

Office Code

Report Formats

Contact information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Payment information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)